Kivitz, Alan <br/><br/>
Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.  [electronic resource] 

 -  Arthritis care & research  Nov 2014 
 - 1653-61 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2151-4658 
<br/><br/><label>Standard No.: </label>10.1002/acr.22384  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Antirheumatic Agents--therapeutic use<br/>Arthritis, Rheumatoid--drug therapy<br/>Dose-Response Relationship, Drug<br/>Double-Blind Method<br/>Drug Therapy, Combination<br/>Female<br/>Humans<br/>Injections, Subcutaneous<br/>Male<br/>Middle Aged<br/>Receptors, Interleukin-6--antagonists & inhibitors<br/>Treatment Outcome